Health & WellnessTech

EnGen Bio

A Vaccine and Therapy to Provide Lifetime Protection from Flu Pandemics
Redwood City, 
Investment type:
(Priced Round)
Target raise:
 - $1,069,999
Minimum investment:​
End date:
May 01, 2022

  • Potential for universal prevention of Type A flu and all flu pandemics in humans and animals.
  • Our vaccine could save 50K-250K lives a year and prevent untold suffering of millions caused by flu.
  • Veterinary applications to prevent all dog, horse, pig and bird flus.
  • Peak sales could reach 2.6B in the U.S. alone, in an $11.4B global market (not guaranteed).
Our Story

EnGen Bio, LLC is a young biotech company focused on discovering and developing a universal influenza vaccine and therapy, and other unmet medical needs.
Our Ambition

We hope that the Company is a drug and vaccine R&D engine. We anticipate having out-licensed and made first distributions on the influenza assets before the 5-year mark, putting us well on the course of being a self-sustaining antibody and vaccine R&D and out-licensing company. The company will remain largely virtual, utilizing the discovery, R&D, clinical, and in/out-licensing expertise of the team. These projections cannot be guaranteed.